Dupont Capital Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Dupont Capital Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-28,410	Closed	-$334K	–	651
2015 Q2	$334K	Buy	28,410 +4,040	+17%	+$56.1K	0.01%	543
2015 Q1	$353K	Buy	24,370 +1,390	+6%	+$21.3K	0.01%	536
2014 Q4	$392K	Sell	22,980 -5,950	-21%	-$85.8K	0.01%	567
2014 Q3	$360K	Sell	28,930 -9,880	-25%	-$122K	0.01%	592
2014 Q2	$569K	Buy	+38,810	New	+$595K	0.01%	568

Other funds holding STML

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dupont Capital Management's STML Position: Q3 2015 in Review

Dupont Capital Management sold out of Stemline Therapeutics, Inc. (STML) in Q3 2015, closing a stake of 28,410 shares — an estimated $334K sold.

Dupont Capital Management first reported a position in STML in Q2 2014 and held it in 5 quarters. The position peaked at $569K in Q2 2014. 62 funds tracked by Wall St. Rank hold STML as of Q3 2015.

Dupont Capital Management reported no remaining Stemline Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
Dupont Capital Management sold 28,410 Stemline Therapeutics, Inc. shares in Q3 2015, an estimated $334K.
Dupont Capital Management first reported a position in Stemline Therapeutics, Inc. in Q2 2014 and held it in 5 quarters.
Dupont Capital Management's Stemline Therapeutics, Inc. position peaked at $569K in Q2 2014.
62 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2015.

Based on Dupont Capital Management's 13F filing for Q3 2015, filed 23 Oct 2015.